Aug 5 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS UPDATE FOLLOWING U.S. FDA APPROVAL OF PHASE 3 CLINICAL TRIAL FOR BUCILLAMINE IN COVID-19
* REVIVE THERAPEUTICS LTD - EXPECTS TO ENGAGE UP TO 10 CLINICAL TRIAL SITES IN U.S. AND OPEN PHASE 3 CLINICAL TRIAL FOR PATIENT SCREENING IN Q3
* REVIVE THERAPEUTICS LTD - FINALIZING VENDOR AGREEMENTS IN PROJECT MANAGEMENT, MEDICAL MONITORING